{
    "medicine_id": "8f3c97ea35a099d670e78914a0ac70b440501bbb",
    "platform_id": "DB06663",
    "metadata": {
        "name": "Signifor 0 3 mg 1mL Injection",
        "composition": "0 3 mg 1mL Pasireotide",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of Cushing s disease specifically for those patients whom pituitary surgery has not been curative or is not an option",
            "contraindications": {
                "disease": "The most common toxic effects observed are hyperglycemia cholelithiasis diarrhea nausea headache abdominal pain fatigue and diabetes mellitus",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Signifor is an analogue of somatostatin that promotes reduced levels of cortisol secretion in Cushing s disease patients",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB08827",
                        "description": "The metabolism of Lomitapide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01200",
                        "description": "The serum concentration of Bromocriptine can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09063",
                        "description": "Pasireotide may increase the bradycardic activities of Ceritinib"
                    },
                    {
                        "drugbank-id": "DB09083",
                        "description": "Pasireotide may increase the bradycardic activities of Ivabradine"
                    },
                    {
                        "drugbank-id": "DB00082",
                        "description": "The risk or severity of increased transaminases can be increased when Pasireotide is combined with Pegvisomant"
                    },
                    {
                        "drugbank-id": "DB08877",
                        "description": "Ruxolitinib may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09039",
                        "description": "The metabolism of Eliglustat can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09053",
                        "description": "The metabolism of Ibrutinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01166",
                        "description": "The metabolism of Cilostazol can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01394",
                        "description": "The metabolism of Colchicine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00813",
                        "description": "The metabolism of Fentanyl can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04946",
                        "description": "The metabolism of Iloperidone can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01256",
                        "description": "The metabolism of Retapamulin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08895",
                        "description": "The metabolism of Tofacitinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00862",
                        "description": "The metabolism of Vardenafil can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00402",
                        "description": "The metabolism of Eszopiclone can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01198",
                        "description": "The metabolism of Zopiclone can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00227",
                        "description": "The metabolism of Lovastatin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00346",
                        "description": "The metabolism of Alfuzosin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00404",
                        "description": "The metabolism of Alprazolam can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00682",
                        "description": "The serum concentration of Warfarin can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01418",
                        "description": "The serum concentration of Acenocoumarol can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08496",
                        "description": "The serum concentration of R warfarin can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08735",
                        "description": "The serum concentration of R S Warfarin alcohol can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08736",
                        "description": "The serum concentration of S R Warfarin alcohol can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB14055",
                        "description": "The serum concentration of S Warfarin can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00683",
                        "description": "The serum concentration of Midazolam can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00864",
                        "description": "The serum concentration of Tacrolimus can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01076",
                        "description": "The metabolism of Atorvastatin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00091",
                        "description": "The bioavailability of Cyclosporine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00030",
                        "description": "The therapeutic efficacy of Insulin human can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00046",
                        "description": "The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00047",
                        "description": "The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00071",
                        "description": "The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00197",
                        "description": "The therapeutic efficacy of Troglitazone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00222",
                        "description": "The therapeutic efficacy of Glimepiride can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00284",
                        "description": "The therapeutic efficacy of Acarbose can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00359",
                        "description": "The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00412",
                        "description": "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00414",
                        "description": "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00491",
                        "description": "The therapeutic efficacy of Miglitol can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00672",
                        "description": "The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00731",
                        "description": "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00839",
                        "description": "The therapeutic efficacy of Tolazamide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00912",
                        "description": "The therapeutic efficacy of Repaglinide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00914",
                        "description": "The therapeutic efficacy of Phenformin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01015",
                        "description": "The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01016",
                        "description": "The therapeutic efficacy of Glyburide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01067",
                        "description": "The therapeutic efficacy of Glipizide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01120",
                        "description": "The therapeutic efficacy of Gliclazide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01124",
                        "description": "The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01132",
                        "description": "The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01251",
                        "description": "The therapeutic efficacy of Gliquidone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01252",
                        "description": "The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01261",
                        "description": "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01276",
                        "description": "The therapeutic efficacy of Exenatide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01277",
                        "description": "The therapeutic efficacy of Mecasermin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01278",
                        "description": "The therapeutic efficacy of Pramlintide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01289",
                        "description": "The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01306",
                        "description": "The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01307",
                        "description": "The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01309",
                        "description": "The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01382",
                        "description": "The therapeutic efficacy of Glymidine can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01700",
                        "description": "The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04830",
                        "description": "The therapeutic efficacy of Buformin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04876",
                        "description": "The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04878",
                        "description": "The therapeutic efficacy of Voglibose can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05115",
                        "description": "The therapeutic efficacy of NN344 can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05819",
                        "description": "The therapeutic efficacy of NBI 6024 can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06011",
                        "description": "The therapeutic efficacy of AMG 222 can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06127",
                        "description": "The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06203",
                        "description": "The therapeutic efficacy of Alogliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06292",
                        "description": "The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06335",
                        "description": "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06655",
                        "description": "The therapeutic efficacy of Liraglutide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08382",
                        "description": "The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08882",
                        "description": "The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08907",
                        "description": "The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08962",
                        "description": "The therapeutic efficacy of Glibornuride can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09022",
                        "description": "The therapeutic efficacy of Benfluorex can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09038",
                        "description": "The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09043",
                        "description": "The therapeutic efficacy of Albiglutide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09045",
                        "description": "The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09198",
                        "description": "The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09199",
                        "description": "The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09200",
                        "description": "The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09201",
                        "description": "The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09265",
                        "description": "The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09456",
                        "description": "The therapeutic efficacy of Insulin beef can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09564",
                        "description": "The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11567",
                        "description": "The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11568",
                        "description": "The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11698",
                        "description": "The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11723",
                        "description": "The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11780",
                        "description": "The therapeutic efficacy of Allicin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11824",
                        "description": "The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11827",
                        "description": "The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11898",
                        "description": "The therapeutic efficacy of 2 4 thiazolidinedione can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11950",
                        "description": "The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11992",
                        "description": "The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12268",
                        "description": "The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12412",
                        "description": "The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12417",
                        "description": "The therapeutic efficacy of Anagliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12625",
                        "description": "The therapeutic efficacy of Evogliptin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12713",
                        "description": "The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12781",
                        "description": "The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12935",
                        "description": "The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB13406",
                        "description": "The therapeutic efficacy of Carbutamide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB13446",
                        "description": "The therapeutic efficacy of Guar gum can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB13675",
                        "description": "The therapeutic efficacy of Metahexamide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB13928",
                        "description": "The therapeutic efficacy of Semaglutide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB14027",
                        "description": "The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB14035",
                        "description": "The therapeutic efficacy of Englitazone can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB15171",
                        "description": "The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB15217",
                        "description": "The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00007",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Leuprolide"
                    },
                    {
                        "drugbank-id": "DB00014",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Goserelin"
                    },
                    {
                        "drugbank-id": "DB00195",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Betaxolol"
                    },
                    {
                        "drugbank-id": "DB00199",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Erythromycin"
                    },
                    {
                        "drugbank-id": "DB00207",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Azithromycin"
                    },
                    {
                        "drugbank-id": "DB00218",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Moxifloxacin"
                    },
                    {
                        "drugbank-id": "DB00243",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ranolazine"
                    },
                    {
                        "drugbank-id": "DB00263",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Sulfisoxazole"
                    },
                    {
                        "drugbank-id": "DB00333",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Methadone"
                    },
                    {
                        "drugbank-id": "DB00343",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Diltiazem"
                    },
                    {
                        "drugbank-id": "DB00391",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Sulpiride"
                    },
                    {
                        "drugbank-id": "DB00393",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Nimodipine"
                    },
                    {
                        "drugbank-id": "DB00420",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Promazine"
                    },
                    {
                        "drugbank-id": "DB00433",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Prochlorperazine"
                    },
                    {
                        "drugbank-id": "DB00450",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Droperidol"
                    },
                    {
                        "drugbank-id": "DB00477",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Chlorpromazine"
                    },
                    {
                        "drugbank-id": "DB00526",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Oxaliplatin"
                    },
                    {
                        "drugbank-id": "DB00537",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ciprofloxacin"
                    },
                    {
                        "drugbank-id": "DB00544",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Fluorouracil"
                    },
                    {
                        "drugbank-id": "DB00556",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Perflutren"
                    },
                    {
                        "drugbank-id": "DB00568",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Cinnarizine"
                    },
                    {
                        "drugbank-id": "DB00571",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Propranolol"
                    },
                    {
                        "drugbank-id": "DB00572",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Atropine"
                    },
                    {
                        "drugbank-id": "DB00608",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Chloroquine"
                    },
                    {
                        "drugbank-id": "DB00625",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Efavirenz"
                    },
                    {
                        "drugbank-id": "DB00640",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Adenosine"
                    },
                    {
                        "drugbank-id": "DB00738",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Pentamidine"
                    },
                    {
                        "drugbank-id": "DB00743",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Gadobenic acid"
                    },
                    {
                        "drugbank-id": "DB00748",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Carbinoxamine"
                    },
                    {
                        "drugbank-id": "DB00757",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dolasetron"
                    },
                    {
                        "drugbank-id": "DB00778",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Roxithromycin"
                    },
                    {
                        "drugbank-id": "DB00779",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Nalidixic acid"
                    },
                    {
                        "drugbank-id": "DB00827",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Cinoxacin"
                    },
                    {
                        "drugbank-id": "DB00836",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Loperamide"
                    },
                    {
                        "drugbank-id": "DB00889",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Granisetron"
                    },
                    {
                        "drugbank-id": "DB00904",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ondansetron"
                    },
                    {
                        "drugbank-id": "DB00922",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Levosimendan"
                    },
                    {
                        "drugbank-id": "DB00933",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Mesoridazine"
                    },
                    {
                        "drugbank-id": "DB00967",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Desloratadine"
                    },
                    {
                        "drugbank-id": "DB00976",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Telithromycin"
                    },
                    {
                        "drugbank-id": "DB00978",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lomefloxacin"
                    },
                    {
                        "drugbank-id": "DB00985",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dimenhydrinate"
                    },
                    {
                        "drugbank-id": "DB01087",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Primaquine"
                    },
                    {
                        "drugbank-id": "DB01113",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Papaverine"
                    },
                    {
                        "drugbank-id": "DB01114",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Chlorpheniramine"
                    },
                    {
                        "drugbank-id": "DB01115",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Nifedipine"
                    },
                    {
                        "drugbank-id": "DB01137",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Levofloxacin"
                    },
                    {
                        "drugbank-id": "DB01155",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Gemifloxacin"
                    },
                    {
                        "drugbank-id": "DB01165",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ofloxacin"
                    },
                    {
                        "drugbank-id": "DB01182",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Propafenone"
                    },
                    {
                        "drugbank-id": "DB01193",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Acebutolol"
                    },
                    {
                        "drugbank-id": "DB01195",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Flecainide"
                    },
                    {
                        "drugbank-id": "DB01211",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Clarithromycin"
                    },
                    {
                        "drugbank-id": "DB01388",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Mibefradil"
                    },
                    {
                        "drugbank-id": "DB01580",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Oxprenolol"
                    },
                    {
                        "drugbank-id": "DB01599",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Probucol"
                    },
                    {
                        "drugbank-id": "DB01615",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Aceprometazine"
                    },
                    {
                        "drugbank-id": "DB02638",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Terlipressin"
                    },
                    {
                        "drugbank-id": "DB04825",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Prenylamine"
                    },
                    {
                        "drugbank-id": "DB04842",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Fluspirilene"
                    },
                    {
                        "drugbank-id": "DB04948",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lofexidine"
                    },
                    {
                        "drugbank-id": "DB04957",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Azimilide"
                    },
                    {
                        "drugbank-id": "DB05223",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Pracinostat"
                    },
                    {
                        "drugbank-id": "DB05488",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Technetium Tc 99m ciprofloxacin"
                    },
                    {
                        "drugbank-id": "DB06160",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Garenoxacin"
                    },
                    {
                        "drugbank-id": "DB06200",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Tedisamil"
                    },
                    {
                        "drugbank-id": "DB06334",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Tucidinostat"
                    },
                    {
                        "drugbank-id": "DB06402",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Telavancin"
                    },
                    {
                        "drugbank-id": "DB06600",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Nemonoxacin"
                    },
                    {
                        "drugbank-id": "DB06712",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Nilvadipine"
                    },
                    {
                        "drugbank-id": "DB08799",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Antazoline"
                    },
                    {
                        "drugbank-id": "DB08903",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Bedaquiline"
                    },
                    {
                        "drugbank-id": "DB08952",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Indenolol"
                    },
                    {
                        "drugbank-id": "DB08980",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Fendiline"
                    },
                    {
                        "drugbank-id": "DB08992",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Eperisone"
                    },
                    {
                        "drugbank-id": "DB09016",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Butriptyline"
                    },
                    {
                        "drugbank-id": "DB09078",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lenvatinib"
                    },
                    {
                        "drugbank-id": "DB09224",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Melperone"
                    },
                    {
                        "drugbank-id": "DB09231",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Benidipine"
                    },
                    {
                        "drugbank-id": "DB09555",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dexchlorpheniramine maleate"
                    },
                    {
                        "drugbank-id": "DB11640",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Amifampridine"
                    },
                    {
                        "drugbank-id": "DB11830",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Mocetinostat"
                    },
                    {
                        "drugbank-id": "DB11841",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Entinostat"
                    },
                    {
                        "drugbank-id": "DB12141",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Gilteritinib"
                    },
                    {
                        "drugbank-id": "DB12174",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with CUDC 101"
                    },
                    {
                        "drugbank-id": "DB12286",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Simendan"
                    },
                    {
                        "drugbank-id": "DB12376",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ricolinostat"
                    },
                    {
                        "drugbank-id": "DB12523",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Mizolastine"
                    },
                    {
                        "drugbank-id": "DB12565",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Abexinostat"
                    },
                    {
                        "drugbank-id": "DB12877",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Oxatomide"
                    },
                    {
                        "drugbank-id": "DB13261",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Sitafloxacin"
                    },
                    {
                        "drugbank-id": "DB13273",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Sultopride"
                    },
                    {
                        "drugbank-id": "DB13500",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Otilonium"
                    },
                    {
                        "drugbank-id": "DB13546",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Nizofenone"
                    },
                    {
                        "drugbank-id": "DB13652",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Bunaftine"
                    },
                    {
                        "drugbank-id": "DB13653",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lorcainide"
                    },
                    {
                        "drugbank-id": "DB13679",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dexchlorpheniramine"
                    },
                    {
                        "drugbank-id": "DB13791",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Penfluridol"
                    },
                    {
                        "drugbank-id": "DB14063",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dexverapamil"
                    },
                    {
                        "drugbank-id": "DB01224",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Quetiapine"
                    },
                    {
                        "drugbank-id": "DB00321",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Amitriptyline"
                    },
                    {
                        "drugbank-id": "DB00458",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Imipramine"
                    },
                    {
                        "drugbank-id": "DB01232",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Saquinavir"
                    },
                    {
                        "drugbank-id": "DB01084",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Emedastine"
                    },
                    {
                        "drugbank-id": "DB11718",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Encorafenib"
                    },
                    {
                        "drugbank-id": "DB00363",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Clozapine"
                    },
                    {
                        "drugbank-id": "DB15982",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Berotralstat"
                    },
                    {
                        "drugbank-id": "DB00166",
                        "description": "The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00176",
                        "description": "The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00328",
                        "description": "The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00476",
                        "description": "The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01149",
                        "description": "The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04832",
                        "description": "The risk or severity of hypoglycemia can be increased when Zimelidine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04884",
                        "description": "The risk or severity of hypoglycemia can be increased when Dapoxetine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04896",
                        "description": "The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06700",
                        "description": "The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Desvenlafaxine"
                    },
                    {
                        "drugbank-id": "DB08918",
                        "description": "The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Levomilnacipran"
                    },
                    {
                        "drugbank-id": "DB08953",
                        "description": "The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Indalpine"
                    },
                    {
                        "drugbank-id": "DB09270",
                        "description": "The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Ubidecarenone"
                    },
                    {
                        "drugbank-id": "DB12693",
                        "description": "The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Ritanserin"
                    },
                    {
                        "drugbank-id": "DB13233",
                        "description": "The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Alaproclate"
                    },
                    {
                        "drugbank-id": "DB14025",
                        "description": "The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Clinafloxacin"
                    },
                    {
                        "drugbank-id": "DB00715",
                        "description": "The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01104",
                        "description": "The risk or severity of hypoglycemia can be increased when Sertraline is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00211",
                        "description": "Midodrine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00264",
                        "description": "Metoprolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00335",
                        "description": "Atenolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00436",
                        "description": "Bendroflumethiazide may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00528",
                        "description": "Lercanidipine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00598",
                        "description": "Labetalol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00612",
                        "description": "Bisoprolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00633",
                        "description": "Dexmedetomidine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00653",
                        "description": "Magnesium sulfate may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00708",
                        "description": "Sufentanil may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00866",
                        "description": "Alprenolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00899",
                        "description": "Remifentanil may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00960",
                        "description": "Pindolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00968",
                        "description": "Methyldopa may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00989",
                        "description": "Rivastigmine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01018",
                        "description": "Guanfacine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01136",
                        "description": "Carvedilol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01203",
                        "description": "Nadolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01295",
                        "description": "Bevantolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01297",
                        "description": "Practolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01359",
                        "description": "Penbutolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04743",
                        "description": "Nimesulide may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04838",
                        "description": "Cyclandelate may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04841",
                        "description": "Flunarizine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04861",
                        "description": "Nebivolol may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04897",
                        "description": "Lucinactant may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04920",
                        "description": "Clevidipine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05885",
                        "description": "Seletracetam may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06152",
                        "description": "Nylidrin may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06218",
                        "description": "Lacosamide may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06415",
                        "description": "Calfactant may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06446",
                        "description": "Dotarizine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06726",
                        "description": "Pasireotide may increase the bradycardic activities of Bufuralol"
                    },
                    {
                        "drugbank-id": "DB06761",
                        "description": "Pasireotide may increase the bradycardic activities of Beractant"
                    },
                    {
                        "drugbank-id": "DB06791",
                        "description": "Pasireotide may increase the bradycardic activities of Lanreotide"
                    },
                    {
                        "drugbank-id": "DB07615",
                        "description": "Pasireotide may increase the bradycardic activities of Tranilast"
                    },
                    {
                        "drugbank-id": "DB08807",
                        "description": "Pasireotide may increase the bradycardic activities of Bopindolol"
                    },
                    {
                        "drugbank-id": "DB08838",
                        "description": "Pasireotide may increase the bradycardic activities of Agmatine"
                    },
                    {
                        "drugbank-id": "DB09113",
                        "description": "Pasireotide may increase the bradycardic activities of Poractant alfa"
                    },
                    {
                        "drugbank-id": "DB09204",
                        "description": "Pasireotide may increase the bradycardic activities of Arotinolol"
                    },
                    {
                        "drugbank-id": "DB09216",
                        "description": "Pasireotide may increase the bradycardic activities of Tolfenamic acid"
                    },
                    {
                        "drugbank-id": "DB09227",
                        "description": "Pasireotide may increase the bradycardic activities of Barnidipine"
                    },
                    {
                        "drugbank-id": "DB09230",
                        "description": "Pasireotide may increase the bradycardic activities of Azelnidipine"
                    },
                    {
                        "drugbank-id": "DB09232",
                        "description": "Pasireotide may increase the bradycardic activities of Cilnidipine"
                    },
                    {
                        "drugbank-id": "DB09234",
                        "description": "Pasireotide may increase the bradycardic activities of Darodipine"
                    },
                    {
                        "drugbank-id": "DB09238",
                        "description": "Pasireotide may increase the bradycardic activities of Manidipine"
                    },
                    {
                        "drugbank-id": "DB09240",
                        "description": "Pasireotide may increase the bradycardic activities of Niludipine"
                    },
                    {
                        "drugbank-id": "DB09351",
                        "description": "Pasireotide may increase the bradycardic activities of Levobetaxolol"
                    },
                    {
                        "drugbank-id": "DB11960",
                        "description": "Pasireotide may increase the bradycardic activities of Carboxyamidotriazole"
                    },
                    {
                        "drugbank-id": "DB12092",
                        "description": "Pasireotide may increase the bradycardic activities of Naftopidil"
                    },
                    {
                        "drugbank-id": "DB12131",
                        "description": "Pasireotide may increase the bradycardic activities of Vinpocetine"
                    },
                    {
                        "drugbank-id": "DB12212",
                        "description": "Pasireotide may increase the bradycardic activities of Landiolol"
                    },
                    {
                        "drugbank-id": "DB12752",
                        "description": "Pasireotide may increase the bradycardic activities of Bucindolol"
                    },
                    {
                        "drugbank-id": "DB13443",
                        "description": "Pasireotide may increase the bradycardic activities of Esatenolol"
                    },
                    {
                        "drugbank-id": "DB13508",
                        "description": "Pasireotide may increase the bradycardic activities of Cloranolol"
                    },
                    {
                        "drugbank-id": "DB13530",
                        "description": "Pasireotide may increase the bradycardic activities of Mepindolol"
                    },
                    {
                        "drugbank-id": "DB13757",
                        "description": "Pasireotide may increase the bradycardic activities of Epanolol"
                    },
                    {
                        "drugbank-id": "DB13775",
                        "description": "Pasireotide may increase the bradycardic activities of Tertatolol"
                    },
                    {
                        "drugbank-id": "DB13835",
                        "description": "Pasireotide may increase the bradycardic activities of Caroverine"
                    },
                    {
                        "drugbank-id": "DB13950",
                        "description": "Pasireotide may increase the bradycardic activities of WIN 55212 2"
                    },
                    {
                        "drugbank-id": "DB13961",
                        "description": "Pasireotide may increase the bradycardic activities of Fish oil"
                    },
                    {
                        "drugbank-id": "DB14064",
                        "description": "Pasireotide may increase the bradycardic activities of Emopamil"
                    },
                    {
                        "drugbank-id": "DB14065",
                        "description": "Pasireotide may increase the bradycardic activities of Lomerizine"
                    },
                    {
                        "drugbank-id": "DB14066",
                        "description": "Pasireotide may increase the bradycardic activities of Tetrandrine"
                    },
                    {
                        "drugbank-id": "DB14068",
                        "description": "Pasireotide may increase the bradycardic activities of Dexniguldipine"
                    },
                    {
                        "drugbank-id": "DB00843",
                        "description": "Donepezil may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00661",
                        "description": "Verapamil may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00381",
                        "description": "Amlodipine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08868",
                        "description": "Pasireotide may increase the bradycardic activities of Fingolimod"
                    },
                    {
                        "drugbank-id": "DB00401",
                        "description": "Nisoldipine may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00802",
                        "description": "Alfentanil may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00215",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Citalopram"
                    },
                    {
                        "drugbank-id": "DB00261",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Anagrelide"
                    },
                    {
                        "drugbank-id": "DB00280",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Disopyramide"
                    },
                    {
                        "drugbank-id": "DB00283",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Clemastine"
                    },
                    {
                        "drugbank-id": "DB00308",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ibutilide"
                    },
                    {
                        "drugbank-id": "DB00313",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Valproic acid"
                    },
                    {
                        "drugbank-id": "DB00365",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Grepafloxacin"
                    },
                    {
                        "drugbank-id": "DB00468",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Quinine"
                    },
                    {
                        "drugbank-id": "DB00489",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Sotalol"
                    },
                    {
                        "drugbank-id": "DB00539",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Toremifene"
                    },
                    {
                        "drugbank-id": "DB00679",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Thioridazine"
                    },
                    {
                        "drugbank-id": "DB00685",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Trovafloxacin"
                    },
                    {
                        "drugbank-id": "DB00834",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Mifepristone"
                    },
                    {
                        "drugbank-id": "DB00875",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Flupentixol"
                    },
                    {
                        "drugbank-id": "DB00907",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Cocaine"
                    },
                    {
                        "drugbank-id": "DB01035",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Procainamide"
                    },
                    {
                        "drugbank-id": "DB01169",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Arsenic trioxide"
                    },
                    {
                        "drugbank-id": "DB01175",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Escitalopram"
                    },
                    {
                        "drugbank-id": "DB01184",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Domperidone"
                    },
                    {
                        "drugbank-id": "DB01208",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Sparfloxacin"
                    },
                    {
                        "drugbank-id": "DB01218",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Halofantrine"
                    },
                    {
                        "drugbank-id": "DB01244",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Bepridil"
                    },
                    {
                        "drugbank-id": "DB01267",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Paliperidone"
                    },
                    {
                        "drugbank-id": "DB01356",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lithium cation"
                    },
                    {
                        "drugbank-id": "DB01405",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Temafloxacin"
                    },
                    {
                        "drugbank-id": "DB01624",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Zuclopenthixol"
                    },
                    {
                        "drugbank-id": "DB04844",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Tetrabenazine"
                    },
                    {
                        "drugbank-id": "DB06216",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Asenapine"
                    },
                    {
                        "drugbank-id": "DB06697",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Artemether"
                    },
                    {
                        "drugbank-id": "DB06708",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lumefantrine"
                    },
                    {
                        "drugbank-id": "DB11730",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ribociclib"
                    },
                    {
                        "drugbank-id": "DB11978",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Glasdegib"
                    },
                    {
                        "drugbank-id": "DB12161",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Deutetrabenazine"
                    },
                    {
                        "drugbank-id": "DB13725",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Terodiline"
                    },
                    {
                        "drugbank-id": "DB00619",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Imatinib"
                    },
                    {
                        "drugbank-id": "DB00342",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Terfenadine"
                    },
                    {
                        "drugbank-id": "DB00604",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Cisapride"
                    },
                    {
                        "drugbank-id": "DB08881",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Vemurafenib"
                    },
                    {
                        "drugbank-id": "DB13925",
                        "description": "Pasireotide may decrease effectiveness of Dotatate gallium Ga 68 as a diagnostic agent"
                    },
                    {
                        "drugbank-id": "DB13985",
                        "description": "The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11637",
                        "description": "Pasireotide may increase the QTc prolonging activities of Delamanid"
                    },
                    {
                        "drugbank-id": "DB01238",
                        "description": "The metabolism of Aripiprazole can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB14185",
                        "description": "The metabolism of Aripiprazole lauroxil can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00230",
                        "description": "The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00390",
                        "description": "The risk or severity of QTc prolongation can be increased when Digoxin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00107",
                        "description": "The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00187",
                        "description": "The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00196",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00220",
                        "description": "The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00245",
                        "description": "The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00270",
                        "description": "The risk or severity of QTc prolongation can be increased when Isradipine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00285",
                        "description": "The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00289",
                        "description": "The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00334",
                        "description": "The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00341",
                        "description": "The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00344",
                        "description": "The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00347",
                        "description": "The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00354",
                        "description": "The risk or severity of QTc prolongation can be increased when Buclizine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00358",
                        "description": "The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00366",
                        "description": "The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00370",
                        "description": "The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00373",
                        "description": "The risk or severity of QTc prolongation can be increased when Timolol is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00374",
                        "description": "The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00405",
                        "description": "The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00424",
                        "description": "The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00427",
                        "description": "The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00434",
                        "description": "The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00467",
                        "description": "The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00487",
                        "description": "The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00503",
                        "description": "The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00529",
                        "description": "The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00543",
                        "description": "The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00555",
                        "description": "The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00582",
                        "description": "The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00613",
                        "description": "The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00622",
                        "description": "The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00674",
                        "description": "The risk or severity of QTc prolongation can be increased when Galantamine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00678",
                        "description": "The risk or severity of QTc prolongation can be increased when Losartan is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00680",
                        "description": "The risk or severity of QTc prolongation can be increased when Moricizine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00691",
                        "description": "The risk or severity of QTc prolongation can be increased when Moexipril is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00697",
                        "description": "The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00710",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00714",
                        "description": "The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00719",
                        "description": "The risk or severity of QTc prolongation can be increased when Azatadine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00734",
                        "description": "The risk or severity of QTc prolongation can be increased when Risperidone is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00753",
                        "description": "The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00808",
                        "description": "The risk or severity of QTc prolongation can be increased when Indapamide is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00817",
                        "description": "The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00818",
                        "description": "The risk or severity of QTc prolongation can be increased when Propofol is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00822",
                        "description": "The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00825",
                        "description": "The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00835",
                        "description": "The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00871",
                        "description": "The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00909",
                        "description": "The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00915",
                        "description": "The risk or severity of QTc prolongation can be increased when Amantadine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00916",
                        "description": "The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00920",
                        "description": "The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00927",
                        "description": "The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00934",
                        "description": "The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00949",
                        "description": "The risk or severity of QTc prolongation can be increased when Felbamate is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00983",
                        "description": "The risk or severity of QTc prolongation can be increased when Formoterol is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00999",
                        "description": "The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01001",
                        "description": "The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01026",
                        "description": "The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01036",
                        "description": "The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01044",
                        "description": "The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01054",
                        "description": "The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01059",
                        "description": "The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01069",
                        "description": "The risk or severity of QTc prolongation can be increased when Promethazine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01071",
                        "description": "The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01072",
                        "description": "The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01074",
                        "description": "The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01075",
                        "description": "The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01106",
                        "description": "The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01151",
                        "description": "The risk or severity of QTc prolongation can be increased when Desipramine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01158",
                        "description": "The risk or severity of QTc prolongation can be increased when Bretylium is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01167",
                        "description": "The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01173",
                        "description": "The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01176",
                        "description": "The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01189",
                        "description": "The risk or severity of QTc prolongation can be increased when Desflurane is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01228",
                        "description": "The risk or severity of QTc prolongation can be increased when Encainide is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01233",
                        "description": "The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01236",
                        "description": "The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01239",
                        "description": "The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01246",
                        "description": "The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01259",
                        "description": "The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01263",
                        "description": "The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01274",
                        "description": "The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01403",
                        "description": "The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01426",
                        "description": "The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01591",
                        "description": "The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01611",
                        "description": "The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01620",
                        "description": "The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01623",
                        "description": "The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB02546",
                        "description": "The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04576",
                        "description": "The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04695",
                        "description": "The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04846",
                        "description": "The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04953",
                        "description": "The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05039",
                        "description": "The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05246",
                        "description": "The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05465",
                        "description": "The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06217",
                        "description": "The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06282",
                        "description": "The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06288",
                        "description": "The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06468",
                        "description": "The risk or severity of QTc prolongation can be increased when Cariporide is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06691",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Mepyramine"
                    },
                    {
                        "drugbank-id": "DB06699",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Degarelix"
                    },
                    {
                        "drugbank-id": "DB06719",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Buserelin"
                    },
                    {
                        "drugbank-id": "DB06788",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Histrelin"
                    },
                    {
                        "drugbank-id": "DB06825",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB07780",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Farnesyl diphosphate"
                    },
                    {
                        "drugbank-id": "DB07841",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Geranylgeranyl diphosphate"
                    },
                    {
                        "drugbank-id": "DB08808",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Bupranolol"
                    },
                    {
                        "drugbank-id": "DB08871",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08893",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Mirabegron"
                    },
                    {
                        "drugbank-id": "DB08936",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Chlorcyclizine"
                    },
                    {
                        "drugbank-id": "DB08972",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Flumequine"
                    },
                    {
                        "drugbank-id": "DB09080",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Olodaterol"
                    },
                    {
                        "drugbank-id": "DB09082",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Vilanterol"
                    },
                    {
                        "drugbank-id": "DB09089",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Trimebutine"
                    },
                    {
                        "drugbank-id": "DB09090",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Pinaverium"
                    },
                    {
                        "drugbank-id": "DB09167",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dosulepin"
                    },
                    {
                        "drugbank-id": "DB09229",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Aranidipine"
                    },
                    {
                        "drugbank-id": "DB09235",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Efonidipine"
                    },
                    {
                        "drugbank-id": "DB09236",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lacidipine"
                    },
                    {
                        "drugbank-id": "DB09239",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Niguldipine"
                    },
                    {
                        "drugbank-id": "DB09488",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Acrivastine"
                    },
                    {
                        "drugbank-id": "DB11390",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Coumaphos"
                    },
                    {
                        "drugbank-id": "DB11397",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dichlorvos"
                    },
                    {
                        "drugbank-id": "DB11408",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Famphur"
                    },
                    {
                        "drugbank-id": "DB11412",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Fenthion"
                    },
                    {
                        "drugbank-id": "DB11443",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Orbifloxacin"
                    },
                    {
                        "drugbank-id": "DB11448",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Phosmet"
                    },
                    {
                        "drugbank-id": "DB11491",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Sarafloxacin"
                    },
                    {
                        "drugbank-id": "DB11511",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Difloxacin"
                    },
                    {
                        "drugbank-id": "DB11591",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Bilastine"
                    },
                    {
                        "drugbank-id": "DB11614",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Rupatadine"
                    },
                    {
                        "drugbank-id": "DB11770",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Talinolol"
                    },
                    {
                        "drugbank-id": "DB11774",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Pazufloxacin"
                    },
                    {
                        "drugbank-id": "DB11785",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Anisodamine"
                    },
                    {
                        "drugbank-id": "DB11891",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with CUDC 907"
                    },
                    {
                        "drugbank-id": "DB11892",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Prulifloxacin"
                    },
                    {
                        "drugbank-id": "DB11943",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Delafloxacin"
                    },
                    {
                        "drugbank-id": "DB12093",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Tetrahydropalmatine"
                    },
                    {
                        "drugbank-id": "DB12231",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Temefos"
                    },
                    {
                        "drugbank-id": "DB12245",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Triclabendazole"
                    },
                    {
                        "drugbank-id": "DB12645",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Givinostat"
                    },
                    {
                        "drugbank-id": "DB12712",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Pilsicainide"
                    },
                    {
                        "drugbank-id": "DB12766",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Cicletanine"
                    },
                    {
                        "drugbank-id": "DB12923",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Gallopamil"
                    },
                    {
                        "drugbank-id": "DB13358",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Cibenzoline"
                    },
                    {
                        "drugbank-id": "DB13488",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Bencyclane"
                    },
                    {
                        "drugbank-id": "DB13555",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Prajmaline"
                    },
                    {
                        "drugbank-id": "DB13627",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Oxolinic acid"
                    },
                    {
                        "drugbank-id": "DB13651",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lorajmine"
                    },
                    {
                        "drugbank-id": "DB13691",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Acetyldigoxin"
                    },
                    {
                        "drugbank-id": "DB13744",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Piromidic acid"
                    },
                    {
                        "drugbank-id": "DB13766",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lidoflazine"
                    },
                    {
                        "drugbank-id": "DB13772",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Rufloxacin"
                    },
                    {
                        "drugbank-id": "DB13823",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Pipemidic acid"
                    },
                    {
                        "drugbank-id": "DB14713",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Inotersen"
                    },
                    {
                        "drugbank-id": "DB00726",
                        "description": "The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00938",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Salmeterol"
                    },
                    {
                        "drugbank-id": "DB01142",
                        "description": "The risk or severity of QTc prolongation can be increased when Doxepin is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01601",
                        "description": "The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00593",
                        "description": "The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01023",
                        "description": "The risk or severity of QTc prolongation can be increased when Felodipine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08815",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lurasidone"
                    },
                    {
                        "drugbank-id": "DB08864",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Rilpivirine"
                    },
                    {
                        "drugbank-id": "DB11742",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ebastine"
                    },
                    {
                        "drugbank-id": "DB00845",
                        "description": "The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11796",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Fostemsavir"
                    },
                    {
                        "drugbank-id": "DB00751",
                        "description": "The risk or severity of QTc prolongation can be increased when Epinastine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11853",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Relugolix"
                    },
                    {
                        "drugbank-id": "DB00186",
                        "description": "The metabolism of Lorazepam can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00191",
                        "description": "The metabolism of Phentermine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00208",
                        "description": "The metabolism of Ticlopidine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00426",
                        "description": "The metabolism of Famciclovir can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00518",
                        "description": "The metabolism of Albendazole can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00567",
                        "description": "The metabolism of Cephalexin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00590",
                        "description": "The metabolism of Doxazosin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00717",
                        "description": "The metabolism of Norethisterone can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01039",
                        "description": "The metabolism of Fenofibrate can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01323",
                        "description": "The metabolism of St John s Wort can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01395",
                        "description": "The metabolism of Drospirenone can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01411",
                        "description": "The metabolism of Pranlukast can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01431",
                        "description": "The metabolism of Allylestrenol can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01656",
                        "description": "The metabolism of Roflumilast can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06201",
                        "description": "The metabolism of Rufinamide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09030",
                        "description": "The metabolism of Vorapaxar can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09034",
                        "description": "The metabolism of Suvorexant can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09048",
                        "description": "The metabolism of Netupitant can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09071",
                        "description": "The metabolism of Tasimelteon can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09079",
                        "description": "The metabolism of Nintedanib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09299",
                        "description": "The metabolism of Tenofovir alafenamide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11094",
                        "description": "The metabolism of Vitamin D can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11273",
                        "description": "The metabolism of Dihydroergocornine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11952",
                        "description": "The metabolism of Duvelisib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12515",
                        "description": "The metabolism of 9 aminocamptothecin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12952",
                        "description": "The metabolism of Methylprednisone can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB13345",
                        "description": "The metabolism of Dihydroergocristine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB13385",
                        "description": "The metabolism of Dihydroergocryptine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB14009",
                        "description": "The metabolism of Medical Cannabis can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB14126",
                        "description": "The metabolism of Tenofovir can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01098",
                        "description": "The metabolism of Rosuvastatin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00549",
                        "description": "The metabolism of Zafirlukast can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB15444",
                        "description": "The metabolism of Elexacaftor can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06717",
                        "description": "The metabolism of Fosaprepitant can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12887",
                        "description": "The metabolism of Tazemetostat can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00247",
                        "description": "The metabolism of Methysergide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00454",
                        "description": "The metabolism of Meperidine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11633",
                        "description": "The metabolism of Isavuconazole can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01268",
                        "description": "The metabolism of Sunitinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06589",
                        "description": "The metabolism of Pazopanib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06603",
                        "description": "The metabolism of Panobinostat can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08865",
                        "description": "The metabolism of Crizotinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB14568",
                        "description": "The metabolism of Ivosidenib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08896",
                        "description": "The metabolism of Regorafenib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00530",
                        "description": "The metabolism of Erlotinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04868",
                        "description": "The metabolism of Nilotinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05294",
                        "description": "The metabolism of Vandetanib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06176",
                        "description": "The metabolism of Romidepsin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00188",
                        "description": "The metabolism of Pasireotide can be decreased when combined with Bortezomib"
                    },
                    {
                        "drugbank-id": "DB00398",
                        "description": "The metabolism of Pasireotide can be decreased when combined with Sorafenib"
                    },
                    {
                        "drugbank-id": "DB00675",
                        "description": "The metabolism of Pasireotide can be decreased when combined with Tamoxifen"
                    },
                    {
                        "drugbank-id": "DB08912",
                        "description": "The metabolism of Dabrafenib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00204",
                        "description": "The metabolism of Dofetilide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00277",
                        "description": "The metabolism of Theophylline can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00564",
                        "description": "The metabolism of Carbamazepine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00877",
                        "description": "The metabolism of Sirolimus can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00908",
                        "description": "The metabolism of Quinidine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00946",
                        "description": "The metabolism of Phenprocoumon can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01008",
                        "description": "The metabolism of Busulfan can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01100",
                        "description": "The metabolism of Pimozide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01118",
                        "description": "The metabolism of Amiodarone can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01223",
                        "description": "The metabolism of Aminophylline can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01229",
                        "description": "The metabolism of Paclitaxel can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01254",
                        "description": "The metabolism of Dasatinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01320",
                        "description": "The metabolism of Fosphenytoin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01396",
                        "description": "The metabolism of Digitoxin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01590",
                        "description": "The metabolism of Everolimus can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04855",
                        "description": "The metabolism of Dronedarone can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05239",
                        "description": "The metabolism of Cobimetinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06287",
                        "description": "The metabolism of Temsirolimus can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09054",
                        "description": "The metabolism of Idelalisib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09289",
                        "description": "The metabolism of Tianeptine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09330",
                        "description": "The metabolism of Osimertinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11963",
                        "description": "The metabolism of Dacomitinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12015",
                        "description": "The metabolism of Alpelisib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01227",
                        "description": "The metabolism of Levacetylmethadol can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01242",
                        "description": "The metabolism of Clomipramine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00575",
                        "description": "The metabolism of Pasireotide can be decreased when combined with Clonidine"
                    },
                    {
                        "drugbank-id": "DB00637",
                        "description": "The metabolism of Astemizole can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00540",
                        "description": "The metabolism of Pasireotide can be decreased when combined with Nortriptyline"
                    },
                    {
                        "drugbank-id": "DB12371",
                        "description": "The metabolism of Siponimod can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00563",
                        "description": "The metabolism of Methotrexate can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00361",
                        "description": "The metabolism of Vinorelbine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00541",
                        "description": "The metabolism of Vincristine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00570",
                        "description": "The metabolism of Vinblastine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00997",
                        "description": "The metabolism of Doxorubicin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01248",
                        "description": "The metabolism of Docetaxel can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04572",
                        "description": "The metabolism of Thiotepa can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05109",
                        "description": "The metabolism of Trabectedin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11363",
                        "description": "The metabolism of Alectinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11581",
                        "description": "The metabolism of Venetoclax can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11641",
                        "description": "The metabolism of Vinflunine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11703",
                        "description": "The metabolism of Acalabrutinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB13874",
                        "description": "The metabolism of Enasidenib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB15035",
                        "description": "The metabolism of Zanubrutinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00248",
                        "description": "The metabolism of Cabergoline can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00309",
                        "description": "The metabolism of Vindesine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00444",
                        "description": "The metabolism of Teniposide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00773",
                        "description": "The metabolism of Etoposide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01181",
                        "description": "The metabolism of Ifosfamide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB04845",
                        "description": "The metabolism of Ixabepilone can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06595",
                        "description": "The metabolism of Midostaurin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06616",
                        "description": "The metabolism of Bosutinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06626",
                        "description": "The metabolism of Axitinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08870",
                        "description": "The metabolism of Brentuximab vedotin can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08901",
                        "description": "The metabolism of Ponatinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09073",
                        "description": "The metabolism of Palbociclib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09143",
                        "description": "The metabolism of Sonidegib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09570",
                        "description": "The metabolism of Ixazomib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11828",
                        "description": "The metabolism of Neratinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12147",
                        "description": "The metabolism of Erdafitinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12267",
                        "description": "The metabolism of Brigatinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12483",
                        "description": "The metabolism of Copanlisib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12978",
                        "description": "The metabolism of Pexidartinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00762",
                        "description": "The metabolism of Irinotecan can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06212",
                        "description": "The metabolism of Tolvaptan can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB08910",
                        "description": "The metabolism of Pomalidomide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09074",
                        "description": "The metabolism of Olaparib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11817",
                        "description": "The metabolism of Baricitinib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB12001",
                        "description": "The metabolism of Abemaciclib can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00320",
                        "description": "The metabolism of Dihydroergotamine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00531",
                        "description": "The metabolism of Cyclophosphamide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00696",
                        "description": "The metabolism of Ergotamine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00872",
                        "description": "The metabolism of Conivaptan can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB01128",
                        "description": "The metabolism of Bicalutamide can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB05773",
                        "description": "The metabolism of Trastuzumab emtansine can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06772",
                        "description": "The metabolism of Cabazitaxel can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06480",
                        "description": "The metabolism of Prucalopride can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB13074",
                        "description": "The therapeutic efficacy of Macimorelin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00331",
                        "description": "The therapeutic efficacy of Metformin can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00656",
                        "description": "The risk or severity of QTc prolongation can be increased when Trazodone is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB11986",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Entrectinib"
                    },
                    {
                        "drugbank-id": "DB11642",
                        "description": "Pasireotide may increase the QTc prolonging activities of Pitolisant"
                    },
                    {
                        "drugbank-id": "DB12825",
                        "description": "Lefamulin may increase the QTc prolonging activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB15494",
                        "description": "Pasireotide may decrease effectiveness of Edotreotide gallium Ga 68 as a diagnostic agent"
                    },
                    {
                        "drugbank-id": "DB11732",
                        "description": "Lasmiditan may increase the bradycardic activities of Pasireotide"
                    },
                    {
                        "drugbank-id": "DB14975",
                        "description": "The serum concentration of Voxelotor can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB09237",
                        "description": "The serum concentration of Levamlodipine can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB15328",
                        "description": "The serum concentration of Ubrogepant can be increased when it is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00557",
                        "description": "The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00193",
                        "description": "The metabolism of Tramadol can be decreased when combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00246",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ziprasidone"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Haloperidol"
                    },
                    {
                        "drugbank-id": "DB00472",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB00104",
                        "description": "The serum concentration of the active metabolites of Pasireotide can be increased when Pasireotide is used in combination with Octreotide"
                    },
                    {
                        "drugbank-id": "DB15873",
                        "description": "The therapeutic efficacy of Pasireotide can be decreased when used in combination with Copper oxodotreotide Cu 64"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}